Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of Prodencel versus investigator's choice treatment in advanced metastatic castration-resistant prostate cancer
CTR20263818Phase 2Active
- Sponsor
- Huidun Biotech
- Start
- Oct 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Prodencel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Huidun Biotech. Started Oct 2026; status: active.
02
Drugs
Prodencel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20263818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263818.